Barbara Yanni
Director/Board Member chez TREVENA, INC.
Fortune : 131 558 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Carrie Bourdow | F | 61 | 9 ans | |
Craig Jalbert | M | 63 | 1 ans | |
Maurice Zauderer | M | 78 | 27 ans | |
Sijmen de Vries | M | 65 | 16 ans | |
Joel S. Solomon | M | - | 9 ans | |
Emmanuel Huynh | M | 54 | 5 ans | |
Deborah Jorn | F | 66 | 5 ans | |
Tom Glocer | M | 63 | 17 ans | |
Jacob Frieberg | M | 67 | 9 ans | |
Chirfi Guindo | M | 58 | 13 ans | |
Robert Young | M | - |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | - |
Robert Yoder | M | 59 | 6 ans | |
Barry Shin | M | 52 | 5 ans | |
Michael Underhill | M | - |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | - |
Mireille Sanders | F | 56 | 5 ans | |
Marvin Johnson | M | 61 | 3 ans | |
Todd L. Wandstrat | M | - | 3 ans | |
Elizabeth Evans | M | 52 | 23 ans | |
Angela Bagley | F | - | 3 ans | |
Ruud van Outersterp | M | 60 | 4 ans | |
Bala S. Manian | M | 77 | 20 ans | |
Anne Phillips | M | 70 | 10 ans | |
Chrystyna Stecyk | F | 61 | 4 ans | |
Michael Levitan | M | 66 | - | |
Peter Wendell | M | 73 | 21 ans | |
Albert Friedberg | M | 77 | 27 ans | |
Leonard Kruimer | M | 66 | 3 ans | |
Jake Nunn | M | 54 | 11 ans | |
Scott Braunstein | M | 60 | 6 ans | |
Dalton Smart | M | 58 | 15 ans | |
Gerald van Strydonck | M | 79 | 21 ans | |
Richard Peters | M | 61 | 1 ans | |
Allan Gabor | M | - | 11 ans | |
Peter Savas | M | 75 |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | - |
Anurag Relan | M | 52 | - | |
Patricia Drake | F | - | 3 ans | |
John Leonard | M | 77 | - | |
Mark Pykett | M | 60 | 4 ans | |
Stephen Toor | M | 52 | 4 ans | |
Ernie Smith | M | 52 | 23 ans | |
Mark Corrigan | M | 66 | 1 ans | |
Jay Mohr | M | - |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | 4 ans |
Jocelyn Jackson | F | - |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | 5 ans |
Grace Wong-Sarad | F | - |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | 9 ans |
Jonathan Polak | M | - |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | - |
Jeroen Wakkerman | M | 55 | 4 ans | |
Mark Demitrack | M | 66 | 6 ans | |
Pamela Eisele | F | - | 15 ans | |
Jabine T. M. van der Meijs | M | 58 | 3 ans | |
William Newell | M | 66 |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | 9 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 77 | 77,00% |
Pays-Bas | 16 | 16,00% |
Canada | 5 | 5,00% |
France | 3 | 3,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Barbara Yanni
- Réseau Personnel